Structure-based optimization of type III indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors

Area of Science:

• Biochemistry
• Immunology
• Medicinal Chemistry

Background:

• Indoleamine 2,3-dioxygenase 1 (IDO1) is a key enzyme in tryptophan metabolism, crucial for immune regulation, neuronal function, and aging.
• IDO1 expression in cancer cells suppresses anti-tumor immune responses, making it a target for cancer immunotherapy.
• IDO1 inhibitors are actively pursued for their therapeutic potential in oncology.

Purpose of the Study:

• To extend a series of potent heme-binding 1,2,3-triazole and 1,2,4-triazole inhibitors targeting IDO1.
• To evaluate the enzymatic and cellular activity of novel IDO1 inhibitors.
• To elucidate structure-activity relationships and understand the impact of structural modifications on inhibitor efficacy.

Main Methods:

• Synthesis and enzymatic inhibition assays for nearly 100 new triazole-based compounds.
• Cellular assays to determine IC50 values.
• X-ray crystallography to obtain structural data of an inhibitor bound to IDO1.
• Computational studies to analyze binding interactions and explain activity trends.

Main Results:

• Identified a lead compound with nanomolar enzymatic and cellular IC50 values (34 nM).
• Generated comprehensive enzymatic inhibition data for an extended series of novel IDO1 inhibitors.
• Obtained X-ray crystal structure of IDO1 in complex with a representative inhibitor.
• Structural and computational analyses revealed key insights into the inhibitor's interaction with the IDO1 active site, particularly concerning pocket B.

Conclusions:

• The study presents highly effective heme-binding triazole inhibitors of IDO1 with significant therapeutic potential for cancer immunotherapy.
• Structural and computational data provide a mechanistic understanding of inhibitor binding and guide future optimization efforts.
• These findings contribute valuable knowledge for the rational design of next-generation IDO1 inhibitors.